Suscribirse

INFLUENZA - 09/09/11

Doi : 10.1016/S0891-5520(05)70406-2 
Nancy J. Cox, PhD *, Keiji Fukuda, MD, MPH *

Resumen

The propensity of influenza viruses to undergo rapid and unpredictable antigenic change has given influenza a prominent place among emerging and reemerging diseases.29, 50, 81 Historical accounts suggest that influenza viruses, which cause a highly contagious, febrile, acute respiratory illness in humans, have been around for centuries.48 Epidemics of various severity have occurred almost annually. Pandemics of influenza, which generally have had a more widespread and dramatic impact than annual epidemics, have occurred unpredictably at irregular intervals.

The three most dramatic events caused by influenza viruses during this century were the pandemics of “Spanish” influenza beginning in 1918, the 1957 “Asian” influenza, and most recently, the 1968 “Hong Kong” influenza. In each pandemic, novel influenza viruses swept rapidly and pervasively around the globe and caused disease in all age groups.78 Each pandemic was associated with high rates of morbidity, considerable social disruption, and substantial economic losses. In addition, the Spanish influenza pandemic was associated with a relatively high case-fatality rate in young and previously healthy adults. This unique pattern of mortality had profound medical, social, and political consequences.13 Although not considered a true pandemic by many,38 the reemergence in 1977 of influenza A (H1N1) viruses (“Russian” influenza) is also notable because these viruses swept rapidly around the globe and caused considerable morbidity among individuals under 20 years of age.78

Two features of influenza virus replication and evolution account for the epidemiologic success of these viruses. First, there is relatively rapid and unpredictable antigenic change (antigenic drift) in the surface proteins, hemagglutinin (HA), and neuraminidase (NA). Antigenic drift occurs as part of the continuing evolution of influenza viruses after they emerge in pandemic form and become established in humans. As antibody levels to the pandemic strain rise within the human population, the circulating influenza viruses must change antigenically to survive. Antigenic drift renders an individual susceptible to new strains because the antigenically drifted influenza viruses are able to escape neutralization by antibody to previously circulating strains. Annual epidemics occur during the interpandemic period because sufficient numbers of individuals in the population become susceptible to the antigenically variant strain.

Second, there is the emergence of novel influenza A viruses in humans (antigenic shift). Antigenic shift occurs when certain animal influenza viruses, which normally infect only avian or swine reservoirs and are unrelated to the influenza viruses currently circulating in humans, are transmitted to humans. Evidence suggests that emergence of novel pandemic strains may occur either after genetic reassortment between human and animal influenza viruses or, alternatively, via direct transmission of an animal strain to humans.80, 81 Thus, antigenic shift is defined as the appearance in the human population of a new influenza virus containing a novel HA or novel HA and NA that are immunologically distinct from those of the influenza viruses that have been circulating in man in recent decades. A pandemic takes place when human-to-human transmission of these novel viruses occurs and leads to disease in a large and immunologically susceptible human population.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Nancy J. Cox, PhD, Influenza Branch, Mailstop G16, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30333


© 1998  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 1997 
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 12 - N° 1

P. 27-38 - mars 1998 Regresar al número
Artículo precedente Artículo precedente
  • HEPATITIS C
  • Miriam J. Alter, Eric E. Mast, Linda A. Moyer, Harold S. Margolis
| Artículo siguiente Artículo siguiente
  • GROUP O HUMAN IMMUNODEFICIENCY VIRUS–1 INFECTIONS
  • Harold W. Jaffe, Gerald Schochetman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.